CLINICAL TRIALS PROFILE FOR LYSERGIC ACID DIETHYLAMIDE
✉ Email this page to a colleague
Clinical Trials for Lysergic Acid Diethylamide
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00920387 ↗ | Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety | Completed | Multidisciplinary Association for Psychedelic Studies | Phase 2 | This study will find out whether psychotherapy combined with lysergic acid diethylamide (LSD) is safe and is helpful in people who are anxious because they have a potentially fatal disease. The study will measure anxiety and quality of life before and after people have two sessions with either full or active placebo dose of LSD. They expect LSD-assisted psychotherapy to reduce anxiety and improve quality of life. |
| NCT01878942 ↗ | Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study | Completed | University Hospital, Basel, Switzerland | Early Phase 1 | The purpose of this study is to characterize the acute psychological, physiological, endocrine, and pharmacokinetic, as well as long-term psychological effects of LSD in humans. |
| NCT02308969 ↗ | Neuronal Correlates of Altered States of Consciousness | Completed | University Hospital, Basel, Switzerland | Early Phase 1 | The aim of the present study is to assess the neuronal correlates of alterations in waking consciousness pharmacologically induced by a 5-hydroxytryptamine (HT)2A receptor agonist in healthy subjects using functional magnetic resonance imaging (fMRI). |
| NCT02451072 ↗ | The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers | Completed | Psychiatric University Hospital, Zurich | N/A | Aim of the present study is to investigate the neuronal correlates of self and of personal meaning as well as the role of the serotonin (5-HT) 2A receptor system in these processes using functional magnetic resonance imaging (fMRI) and psychometric and cognitive measures. |
| NCT03019822 ↗ | Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing | Completed | University Hospital, Basel, Switzerland | Early Phase 1 | The study will test the effect of dopamine, serotonin, and direct 5-HT2A receptor stimulation on empathy, mood perception, and amygdala activity to fearful stimuli. In addition, we predict associations between subjective effects/alterations in emotion processing tests and functional imaging (fMRI) activity. |
| NCT03321136 ↗ | Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study) | Completed | Matthias Liechti | Early Phase 1 | Serotonin receptors, especially the 5HT2A receptor, are thought to be involved in the effects of various recreationally used psychedelic substances such as LSD. LSD potently stimulates the 5-HT2A receptor but also 5-HT2B/C, 5-HT1 and dopaminergic receptors. LSD induces acute transient alterations in waking consciousness including visual perceptual alterations, audio-visual synesthesia, derealization and depersonalization. LSD has therefore been used as experimental tool ("psychotomimetic") in modern psychiatric research to study psychotic-like states and model psychosis in healthy subjects [1-5]. However, the dose-effects of 5-HT2A receptor stimulation by LSD has not yet been studied. Additionally, there is still very limited data to what extent the 5HT2A receptor contributes to LSD's effects and its role in the mediation of the full response to LSD at a high dose is unclear. A recent experimental human study showed the 5-HT2A receptor antagonist ketanserin fully blocked the subjective effects of a moderate dose of 100 µg of LSD [6]. But, whether the effects of a high 200 µg oral dose of LSD can be blocked by the selective pharmacological 5-HT2A antagonist ketanserin remains to be tested to confirm the critical role of the 5-HT2A receptor in more pronounced alterations of consciousness and perception. The present study therefore explores the role the 5-HT2A receptor in LSD-induced altered states of consciousness using escalating doses of LSD and the 5-HT2A receptor blocker ketanserin administered before a high dose of LSD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Lysergic Acid Diethylamide
Condition Name
Clinical Trial Locations for Lysergic Acid Diethylamide
Trials by Country
Clinical Trial Progress for Lysergic Acid Diethylamide
Clinical Trial Phase
Clinical Trial Sponsors for Lysergic Acid Diethylamide
Sponsor Name
